Replies to post #368517 on NorthWest Biotherapeutics Inc (NWBO)

[Karlchen]

YES Yeah Qui Ja , Daniel

Great , AND it was mentioned a few times and i want

REITERATE it again,

because so important
because more than double revenue-potential
which we all didn't anticipate all the time of the trial until 2 years ago:

We will have recurrent GBM - Data ! !

1. secondary endpoint
"The first secondary objective is to compare overall survival (OS) between patients randomized to placebo who received DCVax-L treatment following disease recurrence and control patients from
comparable, contemporaneous clinical trials, in patients with recurrent GBM."